Uric acid and risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention

Verdoia, Monica; Schaffer, Alon; Barbieri, Lucia; Giovine, Gabriella Di; Marino, Paolo; Luca, Giuseppe De

doi:10.1002/dmrr.2495

Cited by 6 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preoperative WBC is independently associated with higher perioperative cardiac enzyme release and mortality after PCI (19). Another study suggests that WBC is not independently associated with PMI (16). The current study is aimed at exploring the connection between the increase of inflammatory biomarkers and the incidence of PMI in patients with elective PCI both in retrospective and prospective manner.…”

Section: Pmi Ratios and Chi-square Test In The Prospective Cohort Studymentioning

confidence: 98%

“…However, four out of the six studies suggested a positive correlation between CRP and PMI while the other two suggested no relationship (8)(9)(10)(11). Furthermore, white blood cell (WBC) count and neutrophil to lymphocyte ratio (NLR) have been shown to have a connection with the extent and prognosis of coronary artery diseases (CAD) (9,10,(12)(13)(14) as well as the incidence of PMI (15) while another study suggested that WBC is not a risk factor of PMI (16) As for NLR, some studies have reported that its increase is connected to the elevated risk of PMI in patients undergoing nonurgent PCI, especially for values ≥3 (15), but Bressi et al demonstrated that there was no relationship between preprocedural NLR values and the PMI incidence (17). There are several clinic indicators that reflect the inflammatory state of the patient and fact that each biomarker can predict the incidence of PMI is controversial and needs further assessment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of increased inflammation biomarkers on periprocedural myocardial infarction in patients undergoing elective percutaneous coronary intervention: a cohort study

Zhao

et al. 2020

J Thorac Dis

View full text Add to dashboard Cite

Background: The fact that each inflammatory indicator has a forecasting capacity on the occurrence of periprocedural myocardial infarction (PMI) has a controversial existence. The purpose of this study was to explore the role of inflammation biological indicators on PMI in a group of patients undergoing selective percutaneous coronary intervention (PCI). Methods: The study was carried out both in a retrospective and prospective manner in 7,413 and 1,189 subjects, respectively. In the retrospective cohort study, the association between inflammation biomarkers and PMI was assessed by univariate and multivariate logistic regression. WBC, CRP, and NLR were distributed using k-means clustering into a virtual variable "Inflammatory Trend", and multivariate logistic regression and subgroup analysis were performed. In the prospective cohort study, the endpoints were PMI, cardiovascular death or cardiac arrest. The chi-square test was performed to calculate the relative risk (RR). Results: In the retrospective cohort study, except WBC, CRP, NLR and virtual variable "Inflammatory trend" were independent risk factors for PMI. The subgroup analysis revealed that CRP can serve as the most stable predictor. In the prospective cohort study, WBC (RR =1.134, P=0.416) has no effect on the incidence of PMI. However, an elevation in the incidence of PMI was observed with an increase of NLR (RR =1.354, P=0.041) and CRP (RR =1.412, P=0.025). Conclusions: In patients with elective PCI for single-vessel lesions, high CRP increases the risk for PMI.The increase of NLR was an independent risk factor for PMI, especially for patients with hypertension and under the age of 70. WBC has no influence on the occurrence of PMI.

show abstract

Section: Pmi Ratios and Chi-square Test In The Prospective Cohort Studymentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Impact of increased inflammation biomarkers on periprocedural myocardial infarction in patients undergoing elective percutaneous coronary intervention: a cohort study

Zhao

et al. 2020

J Thorac Dis

View full text Add to dashboard Cite

show abstract

“…In addition, hyperuricemia may be able to act as a surrogate to unstable coronary plaques [ 46 ], thus presenting a very important practical clinical value, as intravascular ultrasonography is not widely available. Increased baseline SUA levels (≥5.4 mg/dL) were also significantly associated with impaired coronary flow after PCI [ 47 ], without affecting the risk of periprocedural MI [ 48 ].…”

Section: Uric Acid As a Risk Marker For Thrombosis In Different Clinical Scenariosmentioning

confidence: 99%

Uric Acid—An Emergent Risk Marker for Thrombosis?

Țăpoi¹,

Șalaru

Sascău

et al. 2021

JCM

View full text Add to dashboard Cite

Hyperuricemia is nowadays an established cardiovascular risk factor. Experimental studies linked elevated serum uric acid (SUA) levels with endothelial dysfunction (ED), inflammation, and prothrombotic state. The purpose of this review is to summarize the current evidence that emphasizes the possible role of uric acid as a biomarker for a prothrombotic state. A large number of clinical trials correlated SUA levels with both incident and recurrent cases of venous thromboembolism (VTE), independent of other confounding risk factors. Moreover, increased SUA levels may be an important tool for the risk stratification of patients with pulmonary embolism (PE). Left atrial thrombosis was correlated with high SUA levels in several studies and its addition to classical risk scores improved their predictive abilities. In patients with acute myocardial infarction (MI), hyperuricemia was associated with increased mortality, and the idea that hyperuricemia may be able to act as a surrogate to unstable coronary plaques was advanced. Finally, SUA was correlated with an increased risk of thromboembolic events in different systemic diseases. In conclusion, uric acid has been considered a marker of a thrombotic milieu in several clinical scenarios. However, this causality is still controversial, and more experimental and clinical data is needed.

show abstract

Periprocedural Myocardial Injury: Pathophysiology, Prognosis, and Prevention

Soud

Hideo‐Kajita

et al. 2020

Cardiovascular Revascularization Medicine

View full text Add to dashboard Cite

Uric acid and risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention

Abstract: This is the first large study showing that serum uric acid is not associated with an increase in the risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary revascularization.

Cited by 6 publications

References 39 publications

Impact of increased inflammation biomarkers on periprocedural myocardial infarction in patients undergoing elective percutaneous coronary intervention: a cohort study

Impact of increased inflammation biomarkers on periprocedural myocardial infarction in patients undergoing elective percutaneous coronary intervention: a cohort study

Uric Acid—An Emergent Risk Marker for Thrombosis?

Periprocedural Myocardial Injury: Pathophysiology, Prognosis, and Prevention

Contact Info

Product

Resources

About